About | Free Trial

Last Update

2016-04-21T00:00:00.000Z

This profile was last updated on // .

Is this you? Claim your profile.

Wrong Scott Siegel?

Dr. Scott Siegel A. Ph.D.

Vice President of Business Development

Institute for Life Science Entrepreneurship

Direct Phone: (908) ***-**** ext. ***       

Institute for Life Science Entrepreneurship

1000 Morris Ave STEm Bldg.

Union, New Jersey 07083

United States

Company Description

ILSE is an independent non-profit translational research institute founded in 2014. The Institute's mission is to identify and advance early life science innovation by creating a regional ecosystem that can foster start-ups and entrepreneurship. ILSE's mi ... more

Find other employees at this company (8)

Background Information

Employment History

Chief Operating Officer and Vice President, Business Development
Ezose Sciences Inc

Vice President, Corporate Development
Redpoint Bio Corporation

Position, New Business Development
Johnson & Johnson

Adjunct Associate Professor of Microbiology
University of Pennsylvania

Affiliations

Member of Advisory Board
IIR Ltd

Education



Yale University School of Medicine

Bachelor of Science degree
biology
State University of New York , College at New Paltz

MBA
communications
Wharton School

Ph.D.
Biochemistry
SUNY

Ph.D.
Biochemistry
SUNY Downstate Medical Center

Ph.D.
biochemistry
SUNY Downstate Medical

Ph.D.
biochemistry
State University of New York

Web References (76 Total References)


Scott ...

ilsebio.com [cached]

Scott Siegel

...
SCOTT A. SIEGEL, PHD


Scott Siegel, PhD, Vice ...

ilsebio.com [cached]

Scott Siegel, PhD, Vice President of Business Development for Institute for Life Science Entrepreneurship (ILSE) addressed attendees of the organization's second stakeholder forum. Siegel explained how the organization planned to build on early successes and further contribute to the area's life sciences industry and ILSE's mission to accelerate life sciences innovation in medicine, devices and other technologies to improve human health.

...
For information, contact Scott Siegel, PhD, at (908) 737-1922 x104 or ssiegel@ilsebio.com. Visit ILSE online at www.ilsebio.com.
Photos taken during ILSE 2nd Stakeholder Forum, March 8, 2016:
GroupPhoto-Richardson-Siegel-Bostian-Cypess-Connelly
Pictured from left: Dr. Thomas Richardson, VP, Strategic Initiatives, BioNJ; Dr. Scott Siegel, Business Development, ILSE; Dr. Keith Bostian, Interim CEO, ILSE, and Dean, New Jersey Center for Science, Technology & Mathematics (NJCSTM) and Office of Technology Transfer; Dr. Raymond Cypess, CEO, ATCC; Phillip Connelly, EVP, Kean University.


SCOTT A. SIEGEL, ...

ilsebio.com [cached]

SCOTT A. SIEGEL, PHD

...
SCOTT A. SIEGEL, PHD VP BUSINESS DEVELOPMENT
Dr. Scott Siegel brings over 25 years of experience in the biotechnology and pharmaceutical industries and academia to his role at ILSE. He founded Milestone Life Sciences, a consultancy to biotech and pharma companies in strategy, business development and transactions, and currently also serves as a Lecturer in the MBA communications program at the Wharton School. Dr. Siegel was previously COO and VP, Business Development for Ezose Sciences, a Japan-owned "omics" start-up where he built and then led operations, completing transactions across 3 continents. Prior to that he was VP, Corporate Development for Redpoint Bio, a microcap public biotech with unique technology in taste science and diabetes. Dr. Siegel previously spent eight years with Johnson & Johnson in New Business Development and WW Strategic Marketing. His responsibilities spanned scientific and commercial scouting, assessment and alliances across a breadth of technology and product in-licensing opportunities. Prior to J&J he served in various R&D roles including Senior Director, Preclinical R&D for the start-up Phytera, Inc., Associate Director, Immunobiology for Centocor, Inc. and Section Leader, Immunodiagnostics for Becton Dickinson and Co. Dr. Siegel previously also served as Adjunct Associate Professor of Microbiology at the University of Pennsylvania and Executive-in-Residence for the NYU Office of Industrial Liaison and Tech. Transfer.
Dr. Siegel earned his Ph.D. in Biochemistry from SUNY, Downstate Medical Center and completed postdoctoral studies in Pharmacology at the Yale University School of Medicine. He has over 60 publications and patents and has contributed to the development of 3 launched products, including co-inventor of Remicade®, a blockbuster anti-TNF therapy that to-date has been used to treat over 2 million patients with autoimmune disorders.


Scott A. Siegel, PhD ...

www.ilsebio.com [cached]

Scott A. Siegel, PhD


Scott A. Siegel, ...

www.ilsebio.com [cached]

Scott A. Siegel, PhD VP Business Development

...
Dr. Scott Siegel brings over 25 years of experience in the biotechnology and pharmaceutical industries and academia to his role at ILSE. He founded Milestone Life Sciences, a consultancy to biotech and pharma companies in strategy, business development and transactions, and currently also serves as a Lecturer in the MBA communications program at the Wharton School. Dr. Siegel was previously COO and VP, Business Development for Ezose Sciences, a Japan-owned "omics" start-up where he built and then led operations, completing transactions across 3 continents. Prior to that he was VP, Corporate Development for Redpoint Bio, a microcap public biotech with unique technology in taste science and diabetes. Dr. Siegel previously spent eight years with Johnson & Johnson in New Business Development and WW Strategic Marketing. His responsibilities spanned scientific and commercial scouting, assessment and alliances across a breadth of technology and product in-licensing opportunities. Prior to J&J he served in various R&D roles including Senior Director, Preclinical R&D for the start-up Phytera, Inc., Associate Director, Immunobiology for Centocor, Inc. and Section Leader, Immunodiagnostics for Becton Dickinson and Co. Dr. Siegel previously also served as Adjunct Associate Professor of Microbiology at the University of Pennsylvania and Executive-in-Residence for the NYU Office of Industrial Liaison and Tech. Transfer.
Dr. Siegel earned his Ph.D. in Biochemistry from SUNY, Downstate Medical Center and completed postdoctoral studies in Pharmacology at the Yale University School of Medicine. He has over 60 publications and patents and has contributed to the development of 3 launched products, including co-inventor of Remicade®, a blockbuster anti-TNF therapy that to-date has been used to treat over 2 million patients with autoimmune disorders.

Similar Profiles

Other People with this Name

Other people with the name Siegel

Ned Siegel

Stanley Siegel

Alan Siegel
Chiropractic

Howard Siegel
CHEROKEE INC

Bob Siegel
Privacy Ref LLC

Browse ZoomInfo's Business Contact Directory by City

Browse ZoomInfo's
Business People Directory

Browse ZoomInfo's
Advanced Company Directory